Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial

Ewertz, Marianne; Gray, Kathryn P; Regan, Meredith M; Ejlertsen, Bent; Price, Karen N; Thürlimann, Beat; Bonnefoi, Hervé; Forbes, John F; Paridaens, Robert J; Rabaglio, Manuela; Gelber, Richard D; Colleoni, Marco; Láng, István; Smith, Ian E; Coates, Alan S; Goldhirsch, Aron; Mouridsen, Henning T (2012). Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial. Journal of clinical oncology, 30(32), pp. 3967-75. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2011.40.8666

Full text not available from this repository. (Request a copy)

To examine the association of baseline body mass index (BMI) with the risk of recurrence or death in postmenopausal women with early-stage breast cancer receiving adjuvant tamoxifen or letrozole in the Breast International Group (BIG) 1-98 trial at 8.7 years of median follow-up.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Rabaglio, Manuela Elena

ISSN:

0732-183X

Publisher:

American Society of Clinical Oncology

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:36

Last Modified:

02 Mar 2023 23:21

Publisher DOI:

10.1200/JCO.2011.40.8666

PubMed ID:

23045588

Web of Science ID:

000310914800021

URI:

https://boris.unibe.ch/id/eprint/14281 (FactScience: 221157)

Actions (login required)

Edit item Edit item
Provide Feedback